Operator
Good morning, and welcome to the Precision BioSciences Investor Update. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Precision BioSciences website following the conclusion of the event.
I’d now like to turn the call over to Naresh Tanna, Chief of Staff and Head of Investor Relations at Precision BioSciences. Please go ahead, Naresh.
Naresh Tanna
Chief of Staff to CEO & Head of Investor Relations
Thank you. Welcome to Precision BioSciences PBGENE-DMD Investor Update. I’m Naresh Tanna, Head of Investor Relations, and I’m joined by my fellow members of Precision’s management team, including Alex Kelly, Chief Financial Officer; and Dr. Cassie Gorsuch, Chief Scientific Officer. We are also joined by our co-presenters and esteemed members of the key opinion leader community, including Pat Furlong, Founder of Parent Project Muscular Dystrophy, also known as PPMD, a leading DMD advocacy organization.
We’re also joined by Dr. Veerapandiyan, a leading DMD investigator and pediatric neurologists from Arkansas Children’s Hospital.
Next slide, please. Before we begin, I’d like to remind everyone that our remarks today may contain forward-looking statements. These statements are based on current expectations, and actual results could differ materially. Please refer to our latest 10-K and 10-Q filings for a detailed discussion of those risk factors.
Credit: Source link
